المؤلفون: Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM, Yarnold, JR

مصطلحات موضوعية: RA0421, R1, RA

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::363f46fbdd22c1b04d17dfad9580f4d6

المؤلفون: Coles, CE, Griffin, CL, Kirby, AM, Titley, J, Agrawal, RK, Alhasso, A, Bhattacharya, IS, Brunt, AM, Ciurlionis, L, Chan, C, Donovan, EM, Emson, MA, Harnett, AN, Haviland, JS, Hopwood, P, Jefford, ML, Kaggwa, R, Sawyer, EJ, Syndikus, I, Tsang, YM, Wheatley, DA, Wilcox, M, Yarnold, JR, Bliss, JM, Trialists, IMPORT

مصطلحات موضوعية: R735, R1, RA

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::0d6bfce4f3a1b85c4a7f64e7ed042332

المؤلفون: Wheatley Dawn

المصدر: Administration, Vol 70, Iss 3, Pp 7-32 (2022)

مصطلحات موضوعية: government, political communications, media, covid-19, ireland, Political institutions and public administration (General), JF20-2112

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2449-9471

URL الوصول: https://doaj.org/article/54fc8ec86318446ab57aec1a168b6fd0

المؤلفون: Collins Renea, Blombery Peter, Fletcher John, Gibbs Harry, Wheatley David

المصدر: Thrombosis Journal, Vol 9, Iss 1, p 7 (2011)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

Relation: http://www.thrombosisjournal.com/content/9/1/7; https://doaj.org/toc/1477-9560

URL الوصول: https://doaj.org/article/b93912c5c12b414e89b1b6875796b66e

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Wheatley DA; Royal Cornwall Hospital, Treliske, Truro, United Kingdom., Berardi R; AOU delle Marche, Università Politecnica delle Marche, Ancona, Italy., Climent Duran MA; Instituto Valenciano de Oncología, Valencia, Spain., Tomiak A; Kingston Health Sciences Centre, Kingston, Ontario, Canada., Greystoke AP; NU Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom., Joshua AM; St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia., Arkenau HT; Sarah Cannon Research Institute, HCA Healthcare, London, United Kingdom., Géczi L; National Institute of Oncology, Budapest, Hungary., Corbacho JG; Clinic Institute of Hematological and Oncological Diseases, Hospital Clinic, Barcelona, Spain., Paz-Ares LG; Hospital Universitario 12 de Octubre, Madrid, Spain., Hussain SA; Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom., Petruželka L; General University Hospital in Prague, Prague, Czech Republic., Delmonte A; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Chappey C; Pfizer, San Francisco, California., Masters JC; Pfizer, San Diego, California., Michelon E; Pfizer, New York, New York., Murphy DA; Pfizer, San Diego, California., Mwewa S; Pfizer, Paris, France., Cesari R; Pfizer, Milan, Italy., Doger de Spéville B; Fundación Jiménez Díaz University Hospital, Madrid, Spain.

المصدر: Cancer research communications [Cancer Res Commun] 2024 Jun 28; Vol. 4 (6), pp. 1609-1619.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology, Humans ; Female ; Middle Aged ; Male ; Aged ; Carboplatin/administration & dosage ; Carboplatin/therapeutic use ; Carboplatin/adverse effects ; Gemcitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Deoxycytidine/therapeutic use ; Deoxycytidine/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; Cisplatin/adverse effects ; Pemetrexed/therapeutic use ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Adult ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/pathology ; Aged, 80 and over ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/pathology

المؤلفون: Brunt AM; School of Medicine, University of Keele and University Hospitals of North Midlands, Staffordshire, UK.; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Haviland JS; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Wheatley DA; Department of Oncology, Royal Cornwall Hospital NHS Trust, Truro, UK., Sydenham MA; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Bloomfield DJ; Sussex Cancer Centre, Brighton and Sussex University Hospitals, Brighton, UK., Chan C; Women's Health Clinic, Nuffield Health Cheltenham Hospital, Cheltenham, UK., Cleator S; Department of Oncology, Imperial Healthcare NHS Trust, London, UK., Coles CE; Department of Oncology, University of Cambridge, Cambridge, UK., Donovan E; Centre for Vision, Speech and Signal Processing, University of Surrey, Guildford, UK., Fleming H; Clinical and Translational Radiotherapy Research Group, National Cancer Research Institute, London, UK., Glynn D; Centre for Health Economics, University of York, York, UK., Goodman A; Oncology Unit, Torbay Hospital, Devon, UK., Griffin S; Centre for Health Economics, University of York, York, UK., Hopwood P; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Kirby AM; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, UK and Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Kirwan CC; Division of Cancer Sciences, University of Manchester, Manchester, UK., Nabi Z; RTQQA, Mount Vernon Cancer Centre, Middlesex, UK., Patel J; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Sawyer E; Comprehensive Cancer Centre, King's College London, London, UK., Somaiah N; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, UK and Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Syndikus I; Clatterbridge Cancer Centre, Clatterbridge Hospital NHS Trust, Cheshire, UK., Venables K; RTQQA, Mount Vernon Cancer Centre, Middlesex, UK., Yarnold JR; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, UK and Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Bliss JM; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK.

مؤلفون مشاركون: FAST-Forward Trial Management Group

المصدر: Health technology assessment (Winchester, England) [Health Technol Assess] 2023 Nov; Vol. 27 (25), pp. 1-176.

نوع المنشور: Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study

بيانات الدورية: Publisher: NIHR Journals Library Country of Publication: England NLM ID: 9706284 Publication Model: Print Cited Medium: Internet ISSN: 2046-4924 (Electronic) Linking ISSN: 13665278 NLM ISO Abbreviation: Health Technol Assess Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/radiotherapy , Breast Neoplasms*/pathology, Female ; Humans ; Mastectomy ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Radiation Dose Hypofractionation ; Recurrence ; Treatment Outcome

المؤلفون: Joharatnam-Hogan N; MRC Clinical Trials Unit, UCL, London, UK., Hatem D; Department of Safety and Bioethics, Division of Pharmacology, Catholic University School of Medicine, Rome, Italy., Cafferty FH; MRC Clinical Trials Unit, UCL, London, UK.; The Institute of Cancer Research, London, UK., Petrucci G; Department of Safety and Bioethics, Division of Pharmacology, Catholic University School of Medicine, Rome, Italy., Cameron DA; Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, UK., Ring A; The Institute of Cancer Research, London, UK.; The Royal Marsden NHS Foundation Trust, London, UK., Kynaston HG; Department of Urology, Cardiff University School of Medicine, Cardiff, UK., Gilbert DC; MRC Clinical Trials Unit, UCL, London, UK.; University Hospitals Sussex NHS Foundation Trust, Brighton, UK., Wilson RH; School of Cancer Sciences, University of Glasgow, Glasgow, UK.; The Beatson West of Scotland Cancer Centre, Glasgow, UK., Hubner RA; The Christie NHS Foundation Trust, Department of Medical Oncology, Manchester, UK.; University of Manchester, Division of Cancer Sciences, Manchester, UK., Swinson DEB; Leeds Teaching Hospitals NHS Trust, Leeds, UK., Cleary S; MRC Clinical Trials Unit, UCL, London, UK., Robbins A; MRC Clinical Trials Unit, UCL, London, UK., MacKenzie M; Independent Cancer Patients' Voice, London, UK., Scott-Brown MWG; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Sothi S; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Dawson LK; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK., Capaldi LM; Worcestershire Acute Hospitals NHS Trust, Worcester, UK., Churn M; Worcestershire Acute Hospitals NHS Trust, Worcester, UK., Cunningham D; The Royal Marsden NHS Foundation Trust, London, UK., Khoo V; The Institute of Cancer Research, London, UK.; The Royal Marsden NHS Foundation Trust, London, UK., Armstrong AC; The Christie NHS Foundation Trust, Department of Medical Oncology, Manchester, UK., Ainsworth NL; The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK., Horan G; The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, King's Lynn, UK., Wheatley DA; Royal Cornwall Hospitals NHS Trust, Cornwall, UK., Mullen R; The Highland Breast Centre, Raigmore Hospital, Inverness, UK., Lofts FJ; St George's University Hospitals NHS Foundation Trust, London, UK., Walther A; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Herbertson RA; University Hospitals Sussex NHS Foundation Trust, Brighton, UK., Eaton JD; University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK., O'Callaghan A; Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Eichholz A; Buckinghamshire Healthcare NHS Trust, Buckinghamshire, UK., Kagzi MM; South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK., Patterson DM; West Suffolk Hospitals NHS Trust, St Edmunds, UK., Narahari K; University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK.; Division of Cancer and Genetics, Cardiff University, Cardiff, UK., Bradbury J; Salisbury NHS Foundation Trust, Salisbury, UK., Stokes Z; United Lincolnshire Hospitals NHS Trust, Lincoln City, UK., Rizvi AJ; Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK., Walker GA; Nottingham University Hospitals NHS Trust, Nottingham, UK., Kunene VL; Walsall Manor Hospital and University Hospitals, Birmingham NHS Foundation Trust, Birmingham, UK., Srihari N; Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK., Gentry-Maharaj A; MRC Clinical Trials Unit, UCL, London, UK., Meade A; MRC Clinical Trials Unit, UCL, London, UK., Patrono C; Department of Safety and Bioethics, Division of Pharmacology, Catholic University School of Medicine, Rome, Italy., Rocca B; Department of Safety and Bioethics, Division of Pharmacology, Catholic University School of Medicine, Rome, Italy., Langley RE; MRC Clinical Trials Unit, UCL, London, UK. ruth.langley@ucl.ac.uk.

المصدر: British journal of cancer [Br J Cancer] 2023 Sep; Vol. 129 (4), pp. 706-720. Date of Electronic Publication: 2023 Jul 07.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Aspirin* , Colorectal Neoplasms*/drug therapy, Female ; Humans ; Male ; Middle Aged ; Biomarkers ; Creatinine ; Thromboxanes/therapeutic use

المؤلفون: Brunt AM; David Weatherall Building, School of Medicine, University of Keele, Keele, UK; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK. Electronic address: m.brunt@keele.ac.uk., Haviland JS; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Kirby AM; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK., Somaiah N; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK; Department of Radiotherapy, Royal Marsden NHS Foundation Trust, Sutton, UK., Wheatley DA; Sunrise Centre, Royal Cornwall Hospital, Truro, UK., Bliss JM; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Yarnold JR; Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.

المصدر: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2021 Jul; Vol. 33 (7), pp. 430-439. Date of Electronic Publication: 2021 May 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: England NLM ID: 9002902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2981 (Electronic) Linking ISSN: 09366555 NLM ISO Abbreviation: Clin Oncol (R Coll Radiol) Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Female ; Humans ; Mastectomy ; Mastectomy, Segmental ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Radiotherapy, Adjuvant

المؤلفون: Brunt AM; School of Medicine, University of Keele, Staffordshire ST5 5BG, UK. Electronic address: m.brunt@keele.ac.uk., Haviland JS; Institute of Cancer Research, Sutton, London, UK., Wheatley DA; Royal Cornwall Hospital, Treliske, Truro, UK., Yarnold JR; Institute of Cancer Research, Sutton, London, UK.

المصدر: Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1559-1560.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/radiotherapy, Breast ; Humans ; Research